we need therapies that are going to improve women s survival. megyn: why can t we keep it approved until we get it paid for by the insurance companies rather than the women, the superresponders, are going to have to pay for it and what if you re a poor superresponder? this is a great question. we could also say other cancers not that far different, i mean, it s very successful for colon cancer. megyn: is it approved po those? sure, but what are we going dog in the media? giving it a black eye. we re taking away one of its indications. megyn: now you can get it for off-label use because they ve withdrawn approval for it. that s going to be hard with obamacare with a $100,000 price tag. megyn: that s the thing. what troubles me is the european drug regulators the same day says it s approved. only in combination with different drugs. you have to to look at that. they didn t just blanket approval it approve it and it s in certain cases.